Bard Geesaman is an Investor at MPM BioImpact, whose known portfolio counts 15 companies.
Is Bard Geesaman a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- Healthcare
Contacts
Affiliated funds' portfolios
Investor at MPM BioImpact, whose known portfolio counts 15 companies
- Adlai Nortye
- ReCode Therapeutics
- Crossbow Therapeutics
- Protego Biopharma
- Edgewise Therapeutics
- Reunion Neuroscience
- Umoja Biopharma
- Deka Biosciences
- AstronauTx
- DBV Technologies
- NextPoint Therapeutics
- Trevi Therapeutics
- and 3 more
Investor Profile
Bard Geesaman is listed against sector Healthcare, and focus areas Biotech, Clinical Trials, Drug Discovery and Genetics in the database.
MPM BioImpact appears in Growth, Late-Stage and Series A rounds across its known deals.
The firm portfolio and the focus above give founders context on whether Bard Geesaman matches their raise.
Colleagues at MPM BioImpact
Victor Rusu
Principal
Boston, United States
David Kolesky
Principal
Boston, United States
Anna Katharina Traunbauer
Venture Fellow
United States
Detlev Biniszkiewicz
Investment Partner, MPM Capital
Boston, United States
Michael Ehlers
Entrepreneur Partner
Boston, United States
Todd Foley
Managing Director
Boston, United States
Christiana Bardon
Co-Managing Partner
Brookline, United States
Rami Rahal
Principal
Cambridge, United States
John Peng
Managing Partner
Hong Kong
Kazumi Shiosaki
Managing Director
Boston, United States
Ed Hurwitz
Managing Director
Atherton, United States
David Moskowitz
Principal
Boston, United States
Elizabeth Stoner
Executive Partner
Miami Beach, United States
Vinay Bhaskar
Investor
Los Altos, United States
Luke Evnin
Co-Founder
United States
Frequently asked questions
Who is Bard Geesaman?
Bard Geesaman is a private equity investor and venture capital investor based in Boston, Massachusetts, United States, listed as Investor at MPM BioImpact. The known portfolio of that firm counts 15 companies. That portfolio belongs to the firm, not to Bard Geesaman personally.
What does Bard Geesaman invest in?
Listed sectors include Healthcare; listed focus areas include Biotech, Clinical Trials, Drug Discovery and Genetics. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Bard Geesaman invest at?
MPM BioImpact appears in Growth, Late-Stage and Series A rounds across its known deals, and Bard Geesaman is listed there as Investor. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Bard Geesaman listed at?
Bard Geesaman is listed as Investor at MPM BioImpact. 15 other people in the database share a firm with Bard Geesaman.
How do I contact Bard Geesaman?
A LinkedIn page is on file for Bard Geesaman. It is readable inside RaiseHunt after you create an account. The database holds no email address and no phone number for this profile.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal